Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 1–25 of 42 studies in Caregiving (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Showing 42 studies tagged prevalence — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Caregiving” covers

Caregiving — Research on the people doing the caring: their health, their workload, and what support actually helps.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The detailed estimates in this study constitute the best current basis for policymaking, planning, and allocation of health and welfare resources in dementia care. 2 key findings →

Design: systematic review Evidence: high

Depression, anxiety, and apathy symptoms are highly prevalent across dementia stages. 2 key findings →

Design: meta-analysis Participants: 5,897 Evidence: high

Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 68 out of 100. BMJ open 2019-01-25

The strength of the reported associations, the consistency across studies and the suggestion of a dose response supports a need to keep modifiable risk factor exposure to a minimum and to avoid exposure to additional modifiable risks. 3 key findings →

Design: systematic review Evidence: high

The burden of AD dementia is substantial. 5 key findings →

Design: systematic review Participants: 1,000 Evidence: high

Family carers' perceptions of BPSD as challenging are associated with a sense of a declining relationship, transgressions against social norms and underlying beliefs that people with dementia inevitably lose their 'personhood'. 2 key findings →

Design: systematic review Evidence: high

The successful interventions identified included approximately nine to 12 sessions tailored to the needs of the person with dementia and the caregiver and were delivered individually in the home using multiple components over 3-6 months with periodic follow-up. 1 key finding →

Evidence: high

Population-based estimates for the epidemiology of FTD varied widely in the included studies. 2 key findings →

Participants: 1,000 Evidence: low

Incidence and prevalence of dementia in the Cardiovascular Health Study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of the American Geriatrics Society 2004-02-01

Classification resulted in 227 persons with prevalent dementia at entry into the study and 480 incident cases during follow-up. 4 key findings →

Design: cohort study Participants: 227 Evidence: moderate

Behavioural and psychological symptoms of dementia affect nearly all people with dementia. 1 key finding →

Design: longitudinal study Participants: 587 Evidence: moderate

These findings highlight substantial disparities in the timeliness and comprehensiveness of dementia diagnosis. 4 key findings →

Design: cross-sectional Participants: 993 Evidence: low

Projected increases in cases could largely be attributed to population growth and population ageing, although their relative importance varied by world region, with population growth contributing most to the increases in sub-Saharan Africa and population ageing contributing most to the increases in east Asia. 5 key findings →

Evidence: low

Education delays accelerated decline on a memory test in persons who develop dementia

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2007-10-01

As predicted by the cognitive reserve hypothesis, higher education delays the onset of accelerated cognitive decline; once it begins it is more rapid in persons with more education. 1 key finding →

Design: longitudinal study Participants: 117 Evidence: moderate

Sex Differences in Mortality and Health Care Utilization After Dementia Diagnosis

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA Neurology 2025-08-11

A total of 5 721 711 patients (3 302 579 female and 2 419 132 male) with incident dementia between 2014 and 2021 were included in the study. 5 key findings →

Design: cohort study Participants: 711 Evidence: moderate

In tandem with the ever-increasing aging population in low and middle-income countries, the burden of dementia is rising on the African continent. 1 key finding →

Design: longitudinal study Evidence: moderate

A meta-analysis of 27 primary studies was conducted to examine the relationship between neuropsychological functioning and driving ability for adults with dementia. 2 key findings →

Design: meta-analysis Evidence: high

Such complex needs require an integrated response from general health professionals and multidisciplinary dementia specialists. 1 key finding →

Design: cross-sectional Participants: 291,169 Evidence: low

The main cost drivers in dementia: a systematic review

✓ Peer-reviewed alzhub usefulness score 59 out of 100. International journal of geriatric psychiatry 2014-10-16

The results of this review highlight the significant economic burden of dementia for patients, families and healthcare systems and thus are important for future health policy planning. 5 key findings →

Design: systematic review Evidence: high

Increased BPSD was reported in 59.6% of patients as worsening of preexisting symptoms (51.9%) or as new onset (26%), and requested drug modifications in 27.6% of these cases. 4 key findings →

Participants: 4,913 Evidence: low

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 1994-12-01

We developed a new instrument, the Neuropsychiatric Inventory (NPI), to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. 5 key findings →

Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed